ClinicalTrials.gg
RecruitingNCT06113913AMARETTOUpdated Jul 26, 2024

Subcutaneous Infliximab After A Previous Intravenous Dose Optimization

A Phase 4 interventional study of Infliximab and Infliximab in Inflammatory Bowel Diseases, Crohn Disease and Ulcerative Colitis, sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW. Recruiting at 15 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-26.

Sponsored by Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.
  • Started Apr 2024; still recruiting 2 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
275
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing infliximab in Inflammatory Bowel Diseases — 6 open to participants now, 7 under way, none of them phase 3. Infliximab · Inflammatory Bowel Diseases.

Planned enrollment
3rd of 20
275 · median 83
Started
2024
the only one that year
Phase 4
10 of 20
4 open now
Registered
17th of 20
by date
Lead sponsor
1 of 20
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW

Among the 20 studies testing infliximab in Inflammatory Bowel Diseases, this one is the 3rd largest by planned enrollment, is the only one that started in 2024, is one of 10 in phase 4, and was the 17th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

6 of the 20 studies testing infliximab in Inflammatory Bowel Diseases are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing infliximab in Inflammatory Bowel Diseases, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn about the treatment with subcutaneous infliximab in patients with inflammatory bowel disease (IBD) that were previously treated with an optimized dose of intravenous infliximab.

The main question it aims to answer is:

  • Is switching to a weekly dose of subcutaneous infliximab (120 mg) associated with a better outcome compared to the standard fortnightly administration of 120 mg subcutaneous infliximab in patients who received an optimized intravenous dosing schedule?

Participants will switch from intravenous infliximab to subcutaneous infliximab and will be randomized to the intervention arm (Subcutaneous infliximab weekly) or the interventional comparison arm (subcutaneous infliximab bi-weekly). Participants will follow daily clinical practice in the monitoring for clinical and biological remission.

The participants that are willing to switch to subcutaneous infliximab will be compared to a group of participants not willing to switch. These participants will continue to be treated with their optimized intravenous dose of infliximab.

Read the detailed description

Inflammatory bowel diseases (IBD) are a group of immune mediated disorders primarily targeting the gastro-intestinal tract and consist of two distinct phenotypes: Crohn's disease (CD) and ulcerative colitis (UC) that share similarities in both clinical presentation, pathophysiology and treatment. A small proportion of IBD patients cannot be correctly characterized in one of those categories and is referred to as IBD type unclassified (IBDU), which is often classified under UC for clinical research purposes. TNF inhibitors are one of the most frequently prescribed biological therapies and remain an important part of the therapeutic arsenal with international guidelines recommending their use in moderate-to-severe CD and UC when conventional treatments have failed.

Infliximab, a chimer monoclonal antibody against tumor necrosis factor (TNF), was the first anti-TNF agent to be approved for treating IBD as early as 1999. After losing its product patent in 2013, several biosimilars of infliximab have been commercialized including CT-P13. Originally only available in an intravenous (IV) formulation, a subcutaneous (SC) formulation of CT-P13 has been registered for treating moderate-to-severe CD and UC as well. However, many questions on the use of these subcutaneous formulations of infliximab in daily clinical practice remain unanswered, especially in patients who previously required IV dose optimization of infliximab.

The primary objective of the AMARETTO trial is to compare clinical and biological outcome between a regimen with SC infliximab every week and SC infliximab every other week among patients who were in clinical and biological remission with an optimized IV schedule when they switched to SC infliximab.

The secondary objectives of this study are:

  • To compare treatment optimization and discontinuation between a regimen with SC inflixmab every week and SC infliximab every other week among patients who were in clinical and biological remission with an optimized IV schedule when they switched to infliximab SC.
  • To evaluate the willingness and the experience of patients switching to SC infliximab.
  • To compare clinical and biological outcome, as well as treatment optimization and discontinuation between a regimen with SC infliximab (every week or every other week) and IV infliximab among patients who were in clinical and biological remission with an optimized IV schedule.

This study is a national, multicenter, randomized, open-label, prospective, pragmatic trial in Belgium. The trial design is as follows:

  • All subjects will undergo screening procedures. The screening visit of eligible patients will include the review of inclusion and exclusion criteria, and the informed consent form procedure. After screening, if the patient fulfils all inclusion and none of the exclusion criteria, and is willing to participate, the gastroenterologist will record the characteristics of patients and of the disease, medical and surgical history, current and past IBD treatments physical examination, the PRO-2 score about the last 3 days before the visit, blood analysis, stool analysis and patients will be asked to fill in a questionnaire about health-related quality of life.
  • Afterwards the patients will visit the gastroenterologist 4 times in one year (week 0, week 8, week 24 and week 52, however the specific weeks can vary depending on the IV dosing schedule). During these visits a physical examination will be done, the PRO-2 score based on the 3 previous days before the visit will be calculated, a blood analysis and stool analysis will be done, the concomittant medication will be collected and patients will be asked to answer the questionnaire about the health related quality of life.

NOTE: patients that switch to subcutaneous infliximab will be asked to collect all at home administrations in a diary and to additionnaly answer a questionnaire about the satisfaction of switching to subcutaneous infliximab.

03

Conditions studied

  • Inflammatory Bowel Diseases
  • Crohn Disease
  • Ulcerative Colitis

Keywords

  • remission
  • infliximab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written of the participant or their legally authorized representative has been obtained prior to any Screening procedures.
  • Patients with a previously documented CD, UC, IBDU diagnosis confirmed by clinical, endoscopic, histological, and/or radiological criteria
  • Males and females ≥18 years old.
  • Patients must be in -free clinical remission at Screening defined as a rectal bleeding score of 0 and a stool frequency score of ≤1 for patients with UC / IBDU, or an average daily abdominal pain score ≤1 and a liquid stool frequency score ≤2.8 for patients with CD (based on the 3 days before the screening visit, excluding the day of or the day before an eventual endoscopy with bowel preparation) and this without the need for any type of steroids in the previous eight weeks.
  • Patients must be in biological remission at screening defined as a CRP \<10 mg/L and a fecal calprotectin \<250 µg/g.
  • Patients receiving IV infliximab for at least 26 consecutive weeks.
  • Patients receiving a stable IV infliximab dosing schedule for at least 20 weeks.
  • Patients receiving an average IV infliximab dose per 8 weeks based on the two most recent IV administration of more than 8 mg/kg, but not more than 22 mg/kg
  • Patients who speak and read fluently Dutch, French or English.

Exclusion criteria

Exclusion Criteria:

  • Male or female ≤ 18 years
  • Patients with an ileorectal anastomosis, an ileal pouch-anal anastomosis or an ostomy
  • Patients participating in an interventional clinical trial with an Medicinal Product (IMP) or device
  • Patients previously treated with SC infliximab
  • Patients with active perianal fistulizing disease
  • Patients with microscopic colitis
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
275 participants (estimated)

Study arms

  • Experimental
    Interventional (SC infliximab, weekly)

    Participants will switch from an optimized dose of intravenous infliximab to an optimized dose of subcutaneous infliximab. This means the participants will inject 120 mg subcutaneous infliximab every week.

    Drug: Infliximab

  • Experimental
    Interventional comparator (SC infliximab, bi-weekly)

    Participants will switch from an optimized dose of intravenous infliximab to subcutaneous infliximab. This means the participants will inject 120 mg subcutaneous infliximab every other week.

    Drug: Infliximab

  • Active comparator
    Intravenous comparator (IV infliximab, optimized dosing schedule)

    Participants not willing to switch will continue treatment with intravenous infliximab at the same dosing schedule as before.

    Drug: Infliximab

Interventions

  • Weekly administration of subcutaneous infliximab.

  • Bi-weekly administration of subcutaneous infliximab.

  • Optimized dosing schedule of intravenous infliximab.

06

What researchers measure

Primary outcomes

  1. • The proportion of patients that maintain steroid-free clinical and biological remission by week 52 without treatment optimization after switch to SC infliximab (composite endpoint)

    Time frame: week 52

Secondary outcomes

  1. • The proportion of patients that maintain steroid-free clinical and biological remission by week 52 with treatment optimization

    Time frame: week 52

  2. • The proportion of patients that maintain steroid-free clinical and biological remission by week 52 (with or without treatment optimization)

    Time frame: week 52

  3. • The proportion of patients that maintain steroid-free clinical and biological remission by week 8, by week 24 (without treatment optimization)

    Time frame: week 8 and week 24

  4. • The proportion of patients that maintain steroid-free clinical remission by week 8, by week 24, by week 52 (without treatment optimization)

    Time frame: week 8, week 24 and week 54

  5. • The proportion of patients that maintain steroid-free biological remission by week 8, by week 24, by week 52 (without treatment optimization)

    Time frame: week 8, week 24 and week 52

  6. • The proportion of patients switching back to IV infliximab by week 8, by week 24, by week 52

    Time frame: week 6, week 24 and week 52

  7. • Time to an objectified clinical relapse

    Time frame: over 52 weeks

  8. • Time to treatment optimization

    Time frame: over 52 weeks

  9. • Time to treatment discontinuation

    Time frame: over 52 weeks

  10. • Patients experience and satisfaction score with switching to SC therapy by week 8, week 24 and by week 52.

    Patients who switched to subcutaneous infliximab will be asked to answer a satisfaction questionnaire about the subcutaneous administration at each on site visit. This questionnaire involves questions whit answers on a scale from 1 to 10.

    Time frame: week 8, week 24 and week 52

  11. • The proportion of eligible patients willing to switch and effectively switching to SC therapy

    Time frame: week 0

  12. • Identification of reasons for willing or not willing to switch to SC therapy

    During the inclusion visit, patients will be asked why they are willing or not willing to switch to SC infliximab. This is a descriptive outcome.

    Time frame: week 0

  13. • Identification of reasons for treatment optimization (clinical disease activity, biological disease activity, endoscopic disease activity, radiological disease activity, and/or other)

    During the study, it is possible that the patient will need a treatment optimization as sometimes needed in standard of care. The number of patients needing a treatment optimization will be checked as well as the reason for this treatment optimization (descriptive)

    Time frame: over 52 weeks

  14. • Identification of reasons for treatment discontinuation (clinical disease activity, biological disease activity, endoscopic disease activity, radiological disease activity, adverse events, pregnancy, patient's request, and/or other)

    During the study, it is possible that the patient will need to discontinue the infliximab treatment as sometimes needed in standard of care. The number of patients undergoing a treatment discontinuation will be checked as well as the reason for this treatment discontinuation (descriptive)

    Time frame: over 52 weeks

  15. • The number and type of (serious) adverse events by week 52 or 54

    Time frame: week 52

Other outcomes

  1. The association of infliximab trough level and antibody level (if available) at screening to the maintenance of clinical and biological remission after switch to SC infliximab.

    Time frame: Between week 0 and week 52

  2. The association of the IV dosing schedule to the maintenance of clinical and biological remission after switch to SC infliximab.

    Time frame: Between week 0 and week 52

  3. The total cost of infliximab therapy

    Time frame: Between week 0 and week 52

  4. The quality-adjusted life years

    Time frame: Between week 0 and week 52

  5. The total cost to quality-adjusted life year ratio

    Time frame: Between week 0 and week 52

07

Study locations

14 of 15 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for May 2026, 25 months after the start.

Of 33 non-industry phase 4 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 63. This study's planned 25 months is below that.

Counting every sponsor, half of 38 studies reached it within 38 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2023
First posted
Nov 2, 2023
StartActual
Apr 9, 2024
Primary completionEst.
May 2026
CompletionEst.
Nov 2026
Last update
Jul 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06113913
Lead sponsor
Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW
Collaborators
Celltrion
Responsible party
Sponsor
First posted
Nov 2, 2023
Start date
Apr 9, 2024
Primary completion
May 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jul 26, 2024

Study contacts

Ingrid Arijs, Phd
Contact
ingrid.arijs@birdgroup.be
+32499317005
Jolien De Rechter
Contact
jolien.de.rechter@birdgroup.be
+32498748400
Tom Holvoet, MD, PhD
principal investigator · Department of Gastroenterology, VITAZ Sint-Niklaas
Annick Moens, MD, PhD
principal investigator · Department of Gastroenterology Heilig Hartziekenhuis Lier

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infliximab

Start the discussion